These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11175855)

  • 1. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.
    Vigneri P; Wang JY
    Nat Med; 2001 Feb; 7(2):228-34. PubMed ID: 11175855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inviting leukemic cells to waltz with the devil.
    Melo J
    Nat Med; 2001 Feb; 7(2):156-7. PubMed ID: 11175841
    [No Abstract]   [Full Text] [Related]  

  • 3. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
    Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
    Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
    Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
    Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
    Aloisi A; Di Gregorio S; Stagno F; Guglielmo P; Mannino F; Sormani MP; Bruzzi P; Gambacorti-Passerini C; Saglio G; Venuta S; Giustolisi R; Messina A; Vigneri P
    Blood; 2006 Feb; 107(4):1591-8. PubMed ID: 16249386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME; Druker BJ
    Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
    Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
    J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
    Wolff NC; Ilaria RL
    Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
    Preyer M; Vigneri P; Wang JY
    PLoS One; 2011 Feb; 6(2):e17020. PubMed ID: 21347248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME; Druker BJ
    J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X; Layton JE; Elefanty A; Lieschke GJ
    Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa Si
    Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.